CN101792786B - Method for synthesizing cytidine phosphinylidyne compounds through oriented catalysis - Google Patents
Method for synthesizing cytidine phosphinylidyne compounds through oriented catalysis Download PDFInfo
- Publication number
- CN101792786B CN101792786B CN2010101182032A CN201010118203A CN101792786B CN 101792786 B CN101792786 B CN 101792786B CN 2010101182032 A CN2010101182032 A CN 2010101182032A CN 201010118203 A CN201010118203 A CN 201010118203A CN 101792786 B CN101792786 B CN 101792786B
- Authority
- CN
- China
- Prior art keywords
- cytidine
- hours
- cdp
- cmp
- catalysis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 44
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 title claims abstract description 29
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 title claims abstract description 29
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title claims abstract description 29
- 150000001875 compounds Chemical class 0.000 title claims abstract description 24
- 238000006555 catalytic reaction Methods 0.000 title claims abstract description 16
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 49
- 102000004190 Enzymes Human genes 0.000 claims abstract description 15
- 108090000790 Enzymes Proteins 0.000 claims abstract description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 14
- 239000008103 glucose Substances 0.000 claims abstract description 14
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 12
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 12
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 12
- 229960003178 choline chloride Drugs 0.000 claims abstract description 12
- 239000000758 substrate Substances 0.000 claims abstract description 9
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 claims abstract 2
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 claims description 32
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 229910019142 PO4 Inorganic materials 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 230000000977 initiatory effect Effects 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 12
- 239000010452 phosphate Substances 0.000 claims description 12
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 10
- -1 phosphate anion Chemical class 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000235648 Pichia Species 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- PCDQPRRSZKQHHS-CCXZUQQUSA-N Cytarabine Triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-CCXZUQQUSA-N 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 241000722885 Brettanomyces Species 0.000 claims description 2
- 241000235035 Debaryomyces Species 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 241000235649 Kluyveromyces Species 0.000 claims description 2
- 241000192041 Micrococcus Species 0.000 claims description 2
- 241000607720 Serratia Species 0.000 claims description 2
- 241000235017 Zygosaccharomyces Species 0.000 claims description 2
- 238000005273 aeration Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000010170 biological method Methods 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 238000002525 ultrasonication Methods 0.000 claims description 2
- AZRZBCASYOBNKQ-UHFFFAOYSA-N 6-chloro-3,5-diaminopyrazine-3-carboxamide Chemical compound CN(C)C(N)=NC(=O)C1=NC(Cl)=C(N)N=C1N AZRZBCASYOBNKQ-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 8
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- IERHLVCPSMICTF-XVFCMESISA-N CMP group Chemical group P(=O)(O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C(=O)N=C(N)C=C1)O)O IERHLVCPSMICTF-XVFCMESISA-N 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 239000013317 conjugated microporous polymer Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- YWAFNFGRBBBSPD-OCMLZEEQSA-M sodium;[[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound [Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 YWAFNFGRBBBSPD-OCMLZEEQSA-M 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 12
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- 235000021317 phosphate Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000002777 nucleoside Substances 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 238000003916 acid precipitation Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 238000004445 quantitative analysis Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 102000002745 Choline Kinase Human genes 0.000 description 4
- 108010018888 Choline kinase Proteins 0.000 description 4
- 102000015083 Choline-Phosphate Cytidylyltransferase Human genes 0.000 description 4
- 108010078853 Choline-Phosphate Cytidylyltransferase Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 3
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229950004354 phosphorylcholine Drugs 0.000 description 2
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- OTEKOJQFKOIXMU-UHFFFAOYSA-N 1,4-bis(trichloromethyl)benzene Chemical compound ClC(Cl)(Cl)C1=CC=C(C(Cl)(Cl)Cl)C=C1 OTEKOJQFKOIXMU-UHFFFAOYSA-N 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 101001138544 Homo sapiens UMP-CMP kinase Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- XQQSWXUDAPLMKD-UHFFFAOYSA-N N,N-dimethylheptadecan-1-amine hydrobromide Chemical compound Br.CCCCCCCCCCCCCCCCCN(C)C XQQSWXUDAPLMKD-UHFFFAOYSA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical class CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- ALKWJXWZUTYERW-UHFFFAOYSA-L O.O.O.O.[Mn](=O)(Cl)Cl Chemical class O.O.O.O.[Mn](=O)(Cl)Cl ALKWJXWZUTYERW-UHFFFAOYSA-L 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100020797 UMP-CMP kinase Human genes 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960004774 citicoline sodium Drugs 0.000 description 1
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- CNFDGXZLMLFIJV-UHFFFAOYSA-L manganese(II) chloride tetrahydrate Chemical compound O.O.O.O.[Cl-].[Cl-].[Mn+2] CNFDGXZLMLFIJV-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a method for synthesizing cytidine phosphinylidyne compounds through oriented catalysis. The method uses CMP, choline chloride and phosphate ions as substrate, glucose as energy donor and permeable microbial cells as enzyme source and changes the reaction temperature to prepare cytidine phosphinylidyne compounds in the reaction system through oriented catalysis. The method of the invention can be used to produce any one of three substances according to demands, the reaction system is simple and nontoxic, the production cost is low, the control method is simple and practical, and the industrial production and control are greatly facilitated. When CMP is used as substrate, the yield rate of CDP, CTP and CDP-choline are separately 80%, 91.8% and 93.3%.
Description
Technical field
The invention belongs to the biocatalysis technology field, be specifically related to utilize the control technique method of synthesizing cytidine phosphinylidyne compounds through oriented catalysis respectively.
Background technology
Cytidine diphosphate(CDP) (CDP) is a kind of important biochemical reagents as the verivate of cytosine(Cyt).It prepares Polyinosinic-polycytidylic acid (Poly I:C) with the di-phosphate inosine under the effect of nucleotide phosphodiesterase enzyme.Polyinosinic-polycytidylic acid is a kind of interferon inducers efficiently, has broad-spectrum antiviral and immunosuppressive action, is widely used in multiple treatment of diseases.
Cytidine triphosphate(CTP) (CTP) is that termolecular phosphoric acid is combined in the Nucleotide on cytidine ribose 5 '-OH base, is a kind of normal composition in the body cell, distribute extensively, and be the direct precursor of RNA synthetic.It participates in the biosynthetic process of nucleic acid and phospholipids (Yelkin TTS, kephalin, serine phosphatide, sphingophospholipid etc.) in vivo; Phosphatide is the important component of nervous tissue; Also be a kind of natural fat emulsifier, have the brain of perfecting and nervous tissue, increase intelligence with memory and the transportation that promotes body inner cholesterol, fat is arranged; Improve metabolism of fat, thereby prevent the effect of piling up.CTP is widely used in the multiple nerve of treatment, vascular disease as biochemical drug.
Cytidine diphosphate (CDPC) is claimed CITICOLINE SODIUM again, is the agent of brain metabolic activation, can promote the synthetic of neuron membrane Yelkin TTS, has the reparation brain injury, and anoxia improves memory, the effect that increases intelligence, and clinical application is wider.So the synthetic technology of cytidine diphosphate is the research topic that people relatively are concerned about.
CDP, CTP and CDPC all belong to the category of cytidine phosphinylidyne compounds.
At present, the above CDP preparation method of document has two kinds of chemical synthesis and biological synthesis process.Chemical synthesis is to be reactant with CMP, with hexichol phosphoryl chloride phosphorylation, re-refine CDP.This method is used multiple volatile toxic reagent, severe operational environment, and exist yield low, the problem that cost is high (Biochim.Biophys.Acta., 1964,91 (1): 1-13).Biological synthesis process was divided into for two steps, with the synthetic CTP of CMP, again the CTP degraded was generated CDP earlier, can obtain highly purified CDP, and yield is in (chemistry and biotechnology, 2005,22 (7): 52-54) more than 70%.
CTP can utilize mikrobe (is main with cereuisiae fermentum) cellular enzymes system synthetic.The source of this technology required yeasts is wide, and cost is low, receives season limit few; And productive rate is higher, has to excavate to improve potentiality.It is one of main mode of production of present cytidine.According to reports, Kilajima etc. utilize yeast, and from the synthetic CTP of CMP, the reaction yield is 80% (HakkoKogaku Zasshi.1970,48 (12): 753-762).
CDPC compound method at present commonly used is a microbe transformation method, utilizes microbial cell enzyme system synthetic.In yeast cell, CMP can synthesize CDP under the catalysis of nucleoside monophosphate kinase; CDP can generate CTP under the effect of nucleoside diphosphokinase, choline can be under the catalysis of choline kinase synthesizing choline phosphate.CTP and phosphorylcholine can generate CDPC and tetra-sodium through choline phosphate cytidylyltransferase catalysis then.But because cellular enzymes system is complicated, have the feedback regulation effect, transformation efficiency is generally on the low side, and fermentation period is oversize, causes transformation efficiency, product concentration lower, has a large amount of by products in the reaction solution, comprises CMP, CDP and CTP.The at present domestic relevant report of also not utilizing same reaction system through control reaction temperature and the synthetic cytidine phosphinylidyne compounds of time orientation catalysis.
Summary of the invention
Technical problem to be solved by this invention provides the method for the synthetic above-mentioned three kinds of cytidine phosphinylidyne compounds of a kind of microorganism cells directional catalyzing.
For solving the problems of the technologies described above, thinking of the present invention is:
In view of in the preparation process of CDPC, need to consume lot of energy (ATP), therefore in the preparation process of cytidine phosphinylidyne compounds, needing two enzyme systems is regeneration system and the cytidine phosphinylidyne compounds synthetase series of ATP.The regeneration system of ATP is a substrate with the glucose of cheapness, and (EMP) realizes through glycolytic pathway, and this approach is one of most economical approach of energy regeneration; The cytidine phosphinylidyne compounds synthetase series is made up of nucleoside monophosphate kinase, nucleoside diphosphokinase, choline kinase and choline phosphate cytidylyltransferase.
In the whole process of CDPC synthetic, the cytidine phosphinylidyne compounds synthetase series plays keying action by nucleoside monophosphate kinase, nucleoside diphosphokinase, choline kinase and choline phosphate cytidylyltransferase.These enzymes in the cereuisiae fermentum have different optimum temperutures respectively.Four kinds of enzyme optimum temperutures are respectively cytidylate kinase, 25 ℃; Nucleoside diphosphokinase, 37 ℃; Choline kinase, 30 ℃; Choline phosphate cytidylyltransferase, 30 ℃.We can produce any one product among CDP, CTP and the CDPC through control reaction temperature and time.
Key of the present invention is:
1) to have adopted whole-cell catalytic technology, the own enzyme that has directly utilized cell be the synthetic three kinds of cytidine phosphinylidyne compounds of catalysis CMP in the present invention, can produce any one of three kinds of materials according to demand, and reaction system is simple, and is nontoxic, low production cost.
2) the present invention as means, influences the activity of relevant enzyme in the cytidine phosphinylidyne compounds building-up process through control reaction temperature.Under differing temps, the enzymic activity that can help synthetic a kind of material is strengthened, and the enzymic activity that helps generating other materials simultaneously then weakens, and the active selectivity of this kind of enzyme has determined the final product that reacts different.Control device is simple, has greatly made things convenient for the production control in the industriallization.
Concrete technical scheme of the present invention is following:
A kind of method of synthesizing cytidine phosphinylidyne compounds through oriented catalysis; With CMP, choline chloride 60 and phosphate anion is substrate; With glucose as energy donor; The microorganism cells of having property of utilization is the enzyme source, is means through changing temperature of reaction, impels the reaction system biocatalysis to synthesize cytidine phosphinylidyne compounds.
Wherein, said cytidine phosphinylidyne compounds is cytidine diphosphate(CDP) (CDP), cytidine triphosphate(CTP) (CTP) or CDP-choline (CDPC), and its structural formula is following:
Wherein, cytidine monophosphate, i.e. CMP, its structural formula is following:
The method of above-mentioned synthesizing cytidine phosphinylidyne compounds through oriented catalysis is: in the aqueous solution of pH5～10, carry out one of following three kinds of reactions, directed synthetic cytidine phosphinylidyne compounds:
(a) under 28～40 ℃, reacted 3 hours, primary product is CTP;
(b) under 28～40 ℃, reacted 3 hours; Adjust temperature to 28～34 ℃ again, reacted 9～15 hours, primary product is CDPC;
(c) under 28～40 ℃, reacted 3 hours; Adjust temperature to 28～34 ℃ again, reacted 9～15 hours; Adjust temperature to 20～27 ℃ again, reacted 6～10 hours, primary product is CDP.
Wherein, the initial action concentration of substrate CMP is 10～100mmol/L, preferred 20～50mmol/L; The initial action concentration of choline chloride 60 is 10～300mmol/L, preferred 20～150mmol/L; The initial action concentration of phosphate anion is 0.1～2mol/L, preferred 0.2～0.5mol/L; The initial action concentration of glucose is 0.1～1mol/L, preferred 0.2～0.5mol/L; The add-on of microorganism cells is by wet thallus 100～800g/L, preferred 200～600g/L.Phosphate ion can be selected from Tripyrophosphoric acid such as ortho-phosphoric acid, tetra-sodium, tripolyphosphate, inorganic phosphates such as potassium primary phosphate, SODIUM PHOSPHATE, MONOBASIC, Sodium phosphate, dibasic.
Wherein, reaction system also adds Mn
2+The compsn of ion and WR 34678; Mn
2+Initial action concentration is 1～200mmol/L, preferred 10～100mmol/L; WR 34678 initial action concentration is 1～200mmol/L, preferred 10～100mmol/L.
Wherein, described microorganism cells is meant the mikrobe that can utilize the synthetic CDPC of CMP, comprises the bacterium of aerobacter, Escherichia, Serratia, micrococcus sp; The yeast that yeast belong, mycocandida, Pichia, torulopsis, Debaryomyces, zygosaccharomyces genus, genus kluyveromyces, Hansenula and Brettanomyces belong to.Preferred intestinal bacteria, subtilis, yeast saccharomyces cerevisiae or Torulopsis candida.
Wherein, The microorganism cells of described having property is meant the microorganism cells that the permeability changes of the cytolemma of handling through chemistry, physics or biological method is crossed, and concrete grammar comprises surfactant method, organic solvent method, freeze-thaw method, ultrasonication method, aeration drying, freeze-drying or bacteriolyze enzyme process.
The tensio-active agent that uses in the surfactant method is non-ionics polyethylene oxide amines or triton x-100, cationic surfactant hexadecyl trimethylamine bromide, perhaps AS Sarkosyl L salt, and usage quantity is 0.1～50g/L; Preferred 1～20g/L; When being surfactant method processing yeast cell, tensio-active agent directly being added reaction solution, is the reaction solution of 1L for TV; Add 0.1～50g, preferably add 1～20g.
The organic solvent that uses in the organic solvent method is YLENE, toluene, Fatty Alcohol(C12-C14 and C12-C18), acetone or ETHYLE ACETATE; Usage quantity is 0.1～50mL/L, and preferred 1～20mL/L is promptly during organic solvent method process for producing bacterial strain; Organic solvent is directly added reaction solution; For TV is the reaction solution of 1L, adds 0.1～50mL, preferably adds 1～20mL.
It can be the dry thing of yeast cell, the centrifugal cell that obtains of culture of isolated, the lyophilized products of cell, commercially available yeast powder, air-dry yeast or waste yeast mud by fermentation that above-mentioned zymic utilizes form.
Beneficial effect of the present invention is:
The invention provides a kind of method of synthesizing cytidine phosphinylidyne compounds through oriented catalysis; With CMP, choline chloride 60 and phosphate anion is substrate; With glucose as energy donor; The microorganism cells of having property of utilization is the enzyme source, is means through changing temperature of reaction, impels the synthetic cytidine phosphinylidyne compounds of the directed biocatalysis of reaction system.The present invention can produce any a kind of of three kinds of materials according to demand, and reaction system is simple, and is nontoxic, low production cost, and control device is simple, has greatly made things convenient for the production control in the industriallization.The yield of CDP, CTP and CDP-choline can reach 80%, 91.8%, 93.3% respectively when doing substrate with CMP.
Embodiment
According to following embodiment, can understand the present invention better.Yet, those skilled in the art will readily understand that the described concrete material proportion of embodiment, processing condition and result thereof only are used to explain the present invention, and the present invention that should also can not limit in claims to be described in detail.
Embodiment 1:
Yeast culture base: glucose 40g/L, urea 2.0g/L, potassium primary phosphate 1.5g/L, Zinc vitriol 4.0 * 10
-3G/L, Presfersul 3.0 * 10
-3G/L, four hydration Manganous chloride tetrahydrates 0.3 * 10
-3G/L, Calcium Chloride Powder Anhydrous 1.0 * 10
-3G/L, vitamin H 0.05 * 10
-3G/L.
Yeast-inoculated amount 10% was cultivated centrifugal 4000rpm, 20 minutes 24 hours in 30 ℃ of following 120rpm shaking tables.Get yeast slurry ,-7 ℃ of preservations are subsequent use.
Embodiment 2: utilize the directed CTP of production of CMP.
In the reactive tank of capacity 15L, modulate by CMP 300mmol, choline chloride 60 100mmol, glucose 5mol, manganous sulfate 500mmol, WR 34678 300mmol, press the subtilis 2400g of the method cultivation of embodiment 1, potassium primary phosphate 3mol, the reaction solution 10L that triton x-100 1g and water are formed; Using sodium hydroxide to transfer pH is 7.0, and temperature is 35 ℃, reacts and finishes reaction after 3 hours; Use the perchloric acid precipitation, with HPLC product is carried out quantitative analysis, primary product is CDP in the conversion fluid; Its content is 18.6mmol/L; Yield is 62.1%, and this moment, CDP content was 2.5mmol/L, and CDPC content is 5.8mmol/L.
Embodiment 3: utilize the directed CTP of production of CMP.
The reaction solution 10L that yeast saccharomyces cerevisiae 2500g, potassium primary phosphate 3mol, toluene 10mL and the water that modulation is cultivated by CMP 300mmol, choline chloride 60 3000mmol, glucose 5mol, manganous nitrate 500mmol, WR 34678 300mmol, by the method for embodiment 1 in the reactive tank of capacity 15L is formed, use sodium hydroxide accent pH is 7.0, temperature is 40 ℃; React and finish reaction after 3 hours; Use the perchloric acid precipitation, with HPLC product is carried out quantitative analysis, primary product is CDP in the conversion fluid; Its content is 27.5mmol/L; Yield is 91.8%, and this moment, CDP content was 0.7mmol/L, and CDPC content is 0.8mmol/L.
Embodiment 4: utilize the directed CDPC of production of CMP.
In the reactive tank of capacity 15L, modulate by CMP 300mmol, choline chloride 60 3mol, glucose 5mol, manganous sulfate 500mmol, WR 34678 300mmol, press the intestinal bacteria 2500g of the method cultivation of embodiment 1, potassium primary phosphate 3mol, the reaction solution 10L that acetone 10mL and water are formed; Using sodium hydroxide to transfer pH is 7.0, and temperature is 35 ℃, reacts after 3 hours; Temperature is adjusted into 28 ℃, continues reaction and finishes reaction in 9 hours, uses the perchloric acid precipitation; With HPLC product is carried out quantitative analysis, primary product is CDPC in the conversion fluid, and its content is 28mmol/L; Yield is 93.3%, and this moment, CDP content was 0.8mmol/L, and CTP content is 0.3mmol/L.
Embodiment 5: utilize the directed CDPC of production of CMP.
In the reactive tank of capacity 15L, modulate by CMP 300mmol, choline chloride 60 3mol, glucose 5mol, manganous sulfate 500mmol, WR 34678 300mmol, press the pichia spp 2500g of the method cultivation of embodiment 1, the reaction solution 10L that potassium primary phosphate 3mol, ETHYLE ACETATE 10mL and water are formed, using sodium hydroxide to transfer pH is 7.0; Temperature is 40 ℃, reacts after 3 hours, and temperature is adjusted into 34 ℃; Continue reaction and finished reaction in 15 hours, use the perchloric acid precipitation, product is carried out quantitative analysis with HPLC; Primary product is CDPC in the conversion fluid, and its content is 21mmol/L, and yield is 70.0%; This moment, CDP content was 1.2mmol/L, and CTP content is 0.7mmol/L.
Embodiment 6: utilize the directed CDP of production of CMP.
The reaction solution 10L that intestinal bacteria 1000g, SODIUM PHOSPHATE, MONOBASIC 2mol, triton x-100 50g, toluene 50mL and the water that modulation is cultivated by CMP 100mmol, choline chloride 60 100mmol, glucose 1mol, manganous sulfate 20mmol, WR 34678 10mmol, by embodiment 1 method in the reactive tank of capacity 15L is formed, use sodium hydroxide accent pH is 6.0, temperature is 35 ℃; React after 3 hours, temperature is adjusted into 28 ℃, continues reaction 9 hours; Temperature is adjusted into 20 ℃ again, continues reaction and finishes reaction in 6 hours, uses the perchloric acid precipitation; With HPLC product is carried out quantitative analysis; Primary product is CDP in the conversion fluid, and its content is 8mmol/L, and yield is 80.0%; This moment, CTP content was 1mmol/L, and CDPC content is 0.8mmol/L.
Embodiment 7: utilize the directed CDP of production of CMP.
Modulation is pressed the reaction solution 10L of the Torulopsis candida of embodiment 1 method cultivation through 3 8000g of multigelation, SODIUM PHOSPHATE, MONOBASIC 5mol and water composition by CMP 1000mmol, choline chloride 60 3000mmol, glucose 10mol, Manganous chloride tetrahydrate 500mmol, WR 34678 2mol in the reactive tank of capacity 15L, and using sodium hydroxide to transfer pH is 9.0; Temperature is 40 ℃, reacts after 3 hours, and temperature is adjusted into 34 ℃; Continue reaction 15 hours, temperature is adjusted into 27 ℃ again, continues reaction and finishes reaction in 10 hours; Use the perchloric acid precipitation, with HPLC product is carried out quantitative analysis, primary product is CDP in the conversion fluid; Its content is 42mmol/L; Yield is 42.0%, and this moment, CTP content was 0.5mmol/L, and CDPC content is 11mmol/L.
Claims (3)
1. the method for a synthesizing cytidine phosphinylidyne compounds through oriented catalysis; It is characterized in that with CMP, choline chloride 60 and phosphate anion be substrate; With glucose as energy donor; The microorganism cells of having property of utilization is the enzyme source, is means through changing temperature of reaction, impels the reaction system biocatalysis to synthesize cytidine phosphinylidyne compounds;
Wherein, said cytidine phosphinylidyne compounds is cytidine diphosphate(CDP), cytidine triphosphate(CTP) or CDP-choline, and its structural formula is following:
Wherein, described microorganism cells is meant the mikrobe that can utilize the synthetic CDPC of CMP, comprises the bacterium of aerobacter, Escherichia, Serratia, micrococcus sp; The yeast that yeast belong, mycocandida, Pichia, torulopsis, Debaryomyces, zygosaccharomyces genus, genus kluyveromyces, Hansenula and Brettanomyces belong to;
Wherein, The microorganism cells of described having property is meant the microorganism cells that the permeability changes of the cytolemma of handling through chemistry, physics or biological method is crossed, and concrete grammar comprises surfactant method, organic solvent method, freeze-thaw method, ultrasonication method, aeration drying, freeze-drying or bacteriolyze enzyme process;
Wherein, the tensio-active agent that uses in the surfactant method is non-ionics, cationic surfactant or AS, and usage quantity is 0.1～50g/L.
Wherein, the organic solvent that uses in the organic solvent method is YLENE, toluene, Fatty Alcohol(C12-C14 and C12-C18), acetone or ETHYLE ACETATE, and usage quantity is 0.1～50mL/L;
Wherein, in the aqueous solution of pH5～10, carry out one of following three kinds of reactions, directed synthetic cytidine phosphinylidyne compounds:
(a) under 28～40 ℃, reacted 3 hours, primary product is CTP;
(b) under 28～40 ℃, reacted 3 hours; Adjust temperature to 28～34 ℃ again, reacted 9～15 hours, primary product is CDPC;
(c) under 28～40 ℃, reacted 3 hours; Adjust temperature to 28～34 ℃ again, reacted 9～15 hours; Adjust temperature to 20～27 ℃ again, reacted 6～10 hours, primary product is CDP.
2. according to the method for any described synthesizing cytidine phosphinylidyne compounds through oriented catalysis in the claim 1; The initial action concentration that it is characterized in that substrate CMP is 10～100mmol/L; The initial action concentration of choline chloride 60 is 10～300mmol/L; The initial action concentration of phosphate anion is 0.1～2mol/L, and the initial action concentration of glucose is 0.1～1mol/L, and the add-on of microorganism cells is by wet thallus 100～800g/L.
3. according to the method for any described synthesizing cytidine phosphinylidyne compounds through oriented catalysis in the claim 1, it is characterized in that described reaction system also adds Mn
2+The compsn of ion and WR 34678; Mn
2+Initial action concentration is 1～200mmol/L, and WR 34678 initial action concentration is 1～200mmol/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101182032A CN101792786B (en) | 2010-03-04 | 2010-03-04 | Method for synthesizing cytidine phosphinylidyne compounds through oriented catalysis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101182032A CN101792786B (en) | 2010-03-04 | 2010-03-04 | Method for synthesizing cytidine phosphinylidyne compounds through oriented catalysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101792786A CN101792786A (en) | 2010-08-04 |
| CN101792786B true CN101792786B (en) | 2012-07-11 |
Family
ID=42585700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101182032A Expired - Fee Related CN101792786B (en) | 2010-03-04 | 2010-03-04 | Method for synthesizing cytidine phosphinylidyne compounds through oriented catalysis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101792786B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102605025B (en) * | 2011-01-19 | 2014-07-02 | 中国科学院生物物理研究所 | Bioengineering method for synthesis of citicoline |
| CN103436455B (en) * | 2013-08-15 | 2015-07-15 | 南通秋之友生物科技有限公司 | S. cerevisiae strain for producing citicoline through bioconversion and application of S. cerevisiae strain |
| CN108486195A (en) * | 2018-02-26 | 2018-09-04 | 安徽翠鸟生物技术有限公司 | A method of preparing UDP with enzyme process |
| CN111808899A (en) * | 2020-08-31 | 2020-10-23 | 宁波酶赛生物工程有限公司 | Synthesis method of citicoline sodium |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1055202A (en) * | 1990-12-30 | 1991-10-09 | 陕西省微生物研究所 | Technology by nucleic acid direct production nucleoside diphosphate |
| EP0553821A1 (en) * | 1992-01-30 | 1993-08-04 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing cytidine diphosphate choline |
| CN101555509A (en) * | 2009-04-17 | 2009-10-14 | 南京工业大学 | Method for catalyzing and synthesizing uridine phosphinylidyne compound in an oriented way |
-
2010
- 2010-03-04 CN CN2010101182032A patent/CN101792786B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1055202A (en) * | 1990-12-30 | 1991-10-09 | 陕西省微生物研究所 | Technology by nucleic acid direct production nucleoside diphosphate |
| EP0553821A1 (en) * | 1992-01-30 | 1993-08-04 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing cytidine diphosphate choline |
| CN101555509A (en) * | 2009-04-17 | 2009-10-14 | 南京工业大学 | Method for catalyzing and synthesizing uridine phosphinylidyne compound in an oriented way |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101792786A (en) | 2010-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101230373B (en) | Method for preparing S-adenomethionine | |
| CN101805770B (en) | Method for producing cyclic adenosine monophosphate by using whole cell biocatalysis | |
| CN101555509B (en) | Method for catalyzing and synthesizing uridine phosphinylidyne compound in an oriented way | |
| CN101792786B (en) | Method for synthesizing cytidine phosphinylidyne compounds through oriented catalysis | |
| CN1896264A (en) | Preparation of nucleoside triphosphate | |
| CN101979645A (en) | Method for preparing adenosylmethionine | |
| US20230383329A1 (en) | Adenosine-Involved Fully Enzymatic Synthesis Method for NMN | |
| CN101768617B (en) | Novel technology for full cellular biosynthetic deoxyribonucleoside triphosphate | |
| CN102286386B (en) | Issatchenkia orientalis and method for producing citicoline by whole cell conversion of Issatchenkia orientalis | |
| EP0385486B1 (en) | Process for producing fructose-1,6-diphosphate | |
| CN101538598B (en) | Method for preparing citicoline | |
| CN113481262A (en) | NMN semisynthesis method with participation of adenosine | |
| CN101503724B (en) | Novel method for preparing nucleotide by biological phosphorylation technology | |
| CN103540537A (en) | Preparation method of uridine triphosphate | |
| CN112646851B (en) | Method for rapidly preparing beta-nicotinamide mononucleotide by enzyme method | |
| CN102586383B (en) | Process for preparing cytidine diphosphate choline | |
| CN101724670B (en) | Method for combined production of chiral hydroxy ester and uridine phosphinylideyne compounds | |
| AU2020300853B2 (en) | Production of natural organic gluconates | |
| CN1098355C (en) | Acetyl-tyrothricin and process for preparing 5-fluorouridine using same as enzyme precursor | |
| CN101775415B (en) | Method for synthesizing choline phosphate through whole-cell biocatalysis | |
| CN104830930A (en) | Nucleoside drug intermediate 2 '-deoxyguanosine production method | |
| CN101230372B (en) | Method for whole-cell catalytic biosynthesis of uridine diphosphate-N-acetylglucosamine | |
| CN100360667C (en) | Permeable cell trehalose synthease and its preparation and use | |
| JPH05292988A (en) | Production of dinucleoside polyphosphate, nucleoside polyphosphate or their derivative | |
| Bochkov et al. | Hydrolytic approach for production of deoxyribonucleoside-and ribonucleoside-5′-monophosphates and enzymatic synthesis of their polyphosphates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120711 Termination date: 20160304 |